<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02156492</url>
  </required_header>
  <id_info>
    <org_study_id>14467</org_study_id>
    <secondary_id>I1V-MC-EIAM</secondary_id>
    <nct_id>NCT02156492</nct_id>
  </id_info>
  <brief_title>A Study of Evacetrapib With Selected Statins in Healthy Chinese Participants</brief_title>
  <official_title>A Pharmacokinetic, Pharmacodynamic, and Drug-Drug Interaction Study of Evacetrapib With Selected Statins in Healthy Chinese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to investigate how the body responds to evacetrapib and to
      evaluate the safety and the effect of evacetrapib, alone and in combination with selected
      statins, in healthy Chinese participants. The study has 2 parts. Part one will last up to 4
      weeks and part two will last up to 5 weeks, not including screening. Participants may only
      enroll in one part.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics (PK): Area Under Curve (AUC 0-inf) of Evacetrapib</measure>
    <time_frame>Part 1: Day 1 Predose 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 144, and 168 hours Postdose; Part 2 Day 14 Predose 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24 hours Postdose</time_frame>
    <description>Pharmacokinetic (PK) parameter estimates from evacetrapib concentrations following single dose and daily dose of 130 mg evacetrapib.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK: Maximum Concentration (Cmax) of Evacetrapib</measure>
    <time_frame>Part 1: Day 1 and Day 14 Predose 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 144, and 168 hours Postdose; Part 2 Day 14: Predose 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 24 hours Postdose</time_frame>
    <description>Pharmacokinetic parameter estimates from evacetrapib following single dose and daily doses of 130 mg.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK: Time to Maximum Concentration (Tmax) of Evacetrapib</measure>
    <time_frame>Part 1: Day 1 Predose on Day 1 or Day 14 and at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 144, and 168 hours postdose. Part 2: Predose on Day 14 at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 24 hours post dose.</time_frame>
    <description>Pharmacokinetic parameter estimates of evacetrapib following single and daily doses of 130 mg evacetrapib.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK: AUC of Evacetrapib Alone and With Simvastatin or Atorvastatin</measure>
    <time_frame>Part 2: Day 14 and 22 Predose, 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours Postdose</time_frame>
    <description>Pharmacokinetic parameter estimates of evacetrapib following 130 mg evacetrapib daily alone or with 40 mg simvastatin or 20 mg atorvastatin daily AUC (0-24).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK: Cmax of Evacetrapib Alone and With Simvastatin or Atorvastatin</measure>
    <time_frame>Part 2: Day 14 and 22 Predose, 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours Postdose.</time_frame>
    <description>Pharmacokinetic parameter estimates of evacetrapib following 130 mg evacetrapib daily alone or with 40 mg simvastatin or 20 mg atorvastatin daily.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK: Tmax of Evacetrapib Alone and With Simvastatin or Atorvastatin</measure>
    <time_frame>Part 2: Predose on Day 14 and 22 and at 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose.</time_frame>
    <description>Pharmacokinetic parameter estimates of Tmax of evacetrapib following 130 mg daily dose alone or with 40 mg Simvastatin or 20 mg Atorvastatin. Tmax of simvastatin and atorvastatin.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of Evacetrapib Single and Multiple Doses on High Density Lipoprotein Cholesterol (HDL-C), Low Density Lipoprotein Cholesterol (LDL-C), and Triglycerides (TG)</measure>
    <time_frame>Single Dose Day 2 and Multiple Dose Day 22</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">62</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Evacetrapib Single</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1, Cohort A, Period 1, Participants will receive a single oral 130 mg dose of evacetrapib.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Evacetrapib Multiple</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1, Cohort A, Period 2, Participants will receive multiple doses of evacetrapib for 14 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Simvastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Part 2, Cohorts B, Participants will receive simvastatin orally, once daily on Days 1 - 4.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Evacetrapib and Simvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 2, Cohorts B, Participants will receive evacetrapib orally once daily on Days 5 - 14 and simvastatin orally, once daily on Days 15 - 22.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Atorvastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Part 2, Cohorts C, Participants will receive atorvastatin orally, once daily on Days 1 - 4.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Evacetrapib and Atorvastatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 2, Cohorts C, Participants will receive evacetrapib orally once daily on Days 5 - 14 and atorvastatin orally, once daily on Days 15 - 22.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Evacetrapib</intervention_name>
    <description>Administered orally.</description>
    <arm_group_label>Evacetrapib Multiple</arm_group_label>
    <arm_group_label>Evacetrapib Single</arm_group_label>
    <arm_group_label>Evacetrapib and Atorvastatin</arm_group_label>
    <arm_group_label>Evacetrapib and Simvastatin</arm_group_label>
    <other_name>LY2484595</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Simvastatin</intervention_name>
    <description>Administered orally.</description>
    <arm_group_label>Evacetrapib and Simvastatin</arm_group_label>
    <arm_group_label>Simvastatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Atorvastatin</intervention_name>
    <description>Administered orally.</description>
    <arm_group_label>Atorvastatin</arm_group_label>
    <arm_group_label>Evacetrapib and Atorvastatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Are native Chinese and living in China.

          -  Are overtly healthy males or females as determined by medical history and physical
             examination.

          -  Female participants:

               -  Women not of child-bearing potential

               -  Women of child-bearing potential must correctly use 2 forms of reliable
                  contraception to avoid getting pregnant during the study and for 3 months after
                  the study is completed.

          -  Body Mass Index: 19.0 to 24.0 kilogram per square meter (kg/m^2)

          -  BP and pulse rate at both supine and standing positions of approximately a systolic BP
             ≤ 140 millimeter of mercury (mm Hg), and diastolic BP ≤ 90 mm Hg

          -  Participants with untreated hypercholesterolemia may be included if not on an herbal
             or other traditional Chinese medicines (TCM)

          -  Have no known liver disease

          -  Have given written informed consent

        Exclusion Criteria:

          -  Are currently enrolled in a clinical trial involving an investigational product (IP)
             or off-label use of a drug or device, or are concurrently enrolled in any other type
             of medical research judged not to be scientifically or medically compatible with this
             study.

          -  Have known allergies to evacetrapib, simvastatin, or atorvastatin, related compounds
             or any components of the formulation

          -  Have previously completed or withdrawn from this study or any other study
             investigating evacetrapib, and have previously received the IP within 3 months.

          -  Have a history within the last year or presence of cardiovascular, respiratory,
             hepatic, renal, gastrointestinal, endocrine, hematologic, or neurologic disorders
             capable of significantly altering the absorption, metabolism, or elimination of drugs;
             of constituting a risk when taking the study medication; or of interfering with the
             interpretation of data.

          -  Show evidence of significant active neuropsychiatric disease.

          -  Regularly use known drugs of abuse

          -  Are women with a positive pregnancy test or women who are lactating.

          -  Have used or intend to use over-the-counter or prescription medications (including
             vitamins/mineral supplements) or TCM 14 days prior to the first dose and during the
             study.

               -  Hormonal contraceptives are permitted.

          -  Use of any drugs or substances that are known to be substrates, inducers, or
             inhibitors of organic anion transporting polypeptide 1B1 (OATP1B1), or of any other
             transporters involved in simvastatin or atorvastatin disposition, or of any drugs or
             substances that are known to be strong inducers or inhibitors of cytochrome P450 3A
             (CYP3A) within 30 days prior to the first dose and throughout the study.

          -  Donated blood of &gt;400 mL within the last month.

          -  Drink alcoholic beverages with intake that exceeds 28 units per week (males) and 21
             units per week (females), or are unwilling to stop alcohol consumption 48 hours prior
             to dosing until discharge from the clinical research unit (CRU) (1 unit = 12 oz or 360
             mL of beer; 5 oz or 150 mL of wine; 1.5 oz or 45 mL of distilled spirits).

          -  Are unwilling to comply with the dietary requirements/restrictions during the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.</name>
      <address>
        <city>Beijing</city>
        <zip>100034</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2018</verification_date>
  <study_first_submitted>May 28, 2014</study_first_submitted>
  <study_first_submitted_qc>June 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2014</study_first_posted>
  <results_first_submitted>February 18, 2018</results_first_submitted>
  <results_first_submitted_qc>February 18, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">October 10, 2018</results_first_posted>
  <last_update_submitted>February 18, 2018</last_update_submitted>
  <last_update_submitted_qc>February 18, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 10, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atorvastatin</mesh_term>
    <mesh_term>Simvastatin</mesh_term>
    <mesh_term>Evacetrapib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Cohort A: Evacetrapib Single and Multiple Dose</title>
          <description>Part 1, Cohort A, Period 1, Participants will receive a single oral 130 mg dose of evacetrapib.
Part 1, Cohort A, Period 2, Participants will receive multiple doses of evacetrapib 130 mg for 14 days.</description>
        </group>
        <group group_id="P2">
          <title>Cohort B: Evacetrapib and Simvastatin</title>
          <description>Part 2, Cohorts B, Period 1, Participants will receive simvastatin 40 mg orally, once daily on Days 1 – 4
Part 2, Cohorts B, Period 2, Participants will receive a single oral 130 mg dose of evacetrapib on Days 5-14
Part 2, Cohorts B, Period 3, Participants will receive evacetrapib 130 mg and simvastatin 40mg orally, once daily on Days 15 – 22.</description>
        </group>
        <group group_id="P3">
          <title>Cohort C: Evacetrapib and Atorvastatin</title>
          <description>Part 2, Cohorts C, Period 1, Participants will receive atorvastatin orally, once daily on Days 1 – 4.
Part 2, Cohorts C, Period 2, Participants will receive a single oral 130 mg dose of evacetrapib on Days 5-14
Part 2, Cohorts C, Period 3, Participants will receive evacetrapib 130 mg orally and atorvastatin 20 mg orally, once daily on Days 15 – 22.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Period 1</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received at Least One Dose of Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>No Reason Given</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Period 2</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Period 3</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0">Cohort A participated in Period 1 and Period 2 only.</participants>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Participants who received at least one dose of study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>Cohort A</title>
          <description>Part 1, Cohort A, Period 1, Participants will receive a single oral 130 mg dose of evacetrapib.
Part 1, Cohort A, Period 2, Participants will receive multiple doses of evacetrapib 130 mg for 14 days.</description>
        </group>
        <group group_id="B2">
          <title>Cohort B</title>
          <description>Part 2, Cohorts B, Period 1, Participants will receive simvastatin 40 mg orally, once daily on Days 1 - 4.
Part 2, Cohorts B, Period 2, Participants will receive a single oral 130 mg dose of evacetrapib on Days 5-14
Part 2, Cohorts B, Period 3, Participants will receive evacetrapib 130 mg and simvastatin 40mg orally, once daily on Days 15 - 22.</description>
        </group>
        <group group_id="B3">
          <title>Cohort C</title>
          <description>Part 2, Cohorts C, Period 1, Participants will receive atorvastatin orally, once daily on Days 1 - 4.
Part 2, Cohorts C, Period 2, Participants will receive a single oral 130 mg dose of evacetrapib on Days 5-14
Part 2, Cohorts C, Period 3, Participants will receive evacetrapib 130 mg orally and atorvastatin 20 mg orally, once daily on Days 15 - 22.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="24"/>
            <count group_id="B3" value="22"/>
            <count group_id="B4" value="62"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.1" spread="8.0"/>
                    <measurement group_id="B2" value="27.5" spread="2.9"/>
                    <measurement group_id="B3" value="27.9" spread="4.9"/>
                    <measurement group_id="B4" value="28.02" spread="5.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="62"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>China</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Pharmacokinetics (PK): Area Under Curve (AUC 0-inf) of Evacetrapib</title>
        <description>Pharmacokinetic (PK) parameter estimates from evacetrapib concentrations following single dose and daily dose of 130 mg evacetrapib.</description>
        <time_frame>Part 1: Day 1 Predose 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 144, and 168 hours Postdose; Part 2 Day 14 Predose 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24 hours Postdose</time_frame>
        <population>All participants who received at least one dose of study drug in Cohort A.</population>
        <group_list>
          <group group_id="O1">
            <title>Evacetrapib Single and Multiple Dose</title>
            <description>Part 1, Cohort A, Period 1, Participants will receive a single oral 130 mg dose of evacetrapib.
Part 1, Cohort A, Period 2, Participants will receive multiple doses of evacetrapib 130 mg for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics (PK): Area Under Curve (AUC 0-inf) of Evacetrapib</title>
          <description>Pharmacokinetic (PK) parameter estimates from evacetrapib concentrations following single dose and daily dose of 130 mg evacetrapib.</description>
          <population>All participants who received at least one dose of study drug in Cohort A.</population>
          <units>nanogram * hour per milliliter (ng*h/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7700" spread="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23600" spread="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>PK: Maximum Concentration (Cmax) of Evacetrapib</title>
        <description>Pharmacokinetic parameter estimates from evacetrapib following single dose and daily doses of 130 mg.</description>
        <time_frame>Part 1: Day 1 and Day 14 Predose 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 144, and 168 hours Postdose; Part 2 Day 14: Predose 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 24 hours Postdose</time_frame>
        <population>All participants who received at least one dose of study drug in Cohort A.</population>
        <group_list>
          <group group_id="O1">
            <title>Evacetrapib Single and Multiple Dose</title>
            <description>Part 1, Cohort A, Period 1, Participants will receive a single oral 130 mg dose of evacetrapib.
Part 1, Cohort A, Period 2, Participants will receive multiple doses of evacetrapib 130 mg for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>PK: Maximum Concentration (Cmax) of Evacetrapib</title>
          <description>Pharmacokinetic parameter estimates from evacetrapib following single dose and daily doses of 130 mg.</description>
          <population>All participants who received at least one dose of study drug in Cohort A.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Single Dose Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="418" spread="118"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Multiple Dose Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="954" spread="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>PK: Time to Maximum Concentration (Tmax) of Evacetrapib</title>
        <description>Pharmacokinetic parameter estimates of evacetrapib following single and daily doses of 130 mg evacetrapib.</description>
        <time_frame>Part 1: Day 1 Predose on Day 1 or Day 14 and at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 48, 72, 96, 144, and 168 hours postdose. Part 2: Predose on Day 14 at 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 24 hours post dose.</time_frame>
        <population>All participants who received at least one dose of study drug in Cohort A.</population>
        <group_list>
          <group group_id="O1">
            <title>Evacetrapib Single and Multiple Dose</title>
            <description>Part 1, Cohort A, Period 1, Participants will receive a single oral 130 mg dose of evacetrapib.
Part 1, Cohort A, Period 2, Participants will receive multiple doses of evacetrapib 130 mg for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>PK: Time to Maximum Concentration (Tmax) of Evacetrapib</title>
          <description>Pharmacokinetic parameter estimates of evacetrapib following single and daily doses of 130 mg evacetrapib.</description>
          <population>All participants who received at least one dose of study drug in Cohort A.</population>
          <units>hours (h)</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Single Dose Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.00" lower_limit="2.00" upper_limit="6.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Daily Dose Day 14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.00" lower_limit="2.00" upper_limit="4.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>PK: AUC of Evacetrapib Alone and With Simvastatin or Atorvastatin</title>
        <description>Pharmacokinetic parameter estimates of evacetrapib following 130 mg evacetrapib daily alone or with 40 mg simvastatin or 20 mg atorvastatin daily AUC (0-24).</description>
        <time_frame>Part 2: Day 14 and 22 Predose, 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours Postdose</time_frame>
        <population>All participants who received at least one dose of study drug in Cohort B and C and had evaluable PK data</population>
        <group_list>
          <group group_id="O1">
            <title>Evacetrapib Daily and Simvastatin</title>
            <description>Part 2, Cohorts B, Period 2, Participants will receive a single oral 130 mg dose of evacetrapib on Days 5-14.
Part 2, Cohorts B, Period 3, Participants will receive evacetrapib 130 mg and simvastatin 40mg orally, once daily on Days 15 - 22.</description>
          </group>
          <group group_id="O2">
            <title>Evacetrapib Daily and Atorvastatin</title>
            <description>Part 2, Cohorts C, Period 2, Participants will receive a single oral 130 mg dose of evacetrapib on Days 5-14.
Part 2, Cohorts C, Period 3, Participants will receive evacetrapib 130 mg orally and atorvastatin 20 mg orally, once daily on Days 15 - 22.</description>
          </group>
        </group_list>
        <measure>
          <title>PK: AUC of Evacetrapib Alone and With Simvastatin or Atorvastatin</title>
          <description>Pharmacokinetic parameter estimates of evacetrapib following 130 mg evacetrapib daily alone or with 40 mg simvastatin or 20 mg atorvastatin daily AUC (0-24).</description>
          <population>All participants who received at least one dose of study drug in Cohort B and C and had evaluable PK data</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Days 5-14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10700" spread="36"/>
                    <measurement group_id="O2" value="10600" spread="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 15-22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9640" spread="48"/>
                    <measurement group_id="O2" value="9480" spread="53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>PK: Cmax of Evacetrapib Alone and With Simvastatin or Atorvastatin</title>
        <description>Pharmacokinetic parameter estimates of evacetrapib following 130 mg evacetrapib daily alone or with 40 mg simvastatin or 20 mg atorvastatin daily.</description>
        <time_frame>Part 2: Day 14 and 22 Predose, 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours Postdose.</time_frame>
        <population>All participants who received at least one dose of study drug in Cohort B and C and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>Evacetrapib Daily and Simvastatin</title>
            <description>Part 2, Cohorts B, Period 2, Participants will receive a single oral 130 mg dose of evacetrapib on Days 5-14.
Part 2, Cohorts B, Period 3, Participants will receive evacetrapib 130 mg and simvastatin 40mg orally, once daily on Days 15 - 22.</description>
          </group>
          <group group_id="O2">
            <title>Evactrapib Daily and Atorvastatin</title>
            <description>Part 2, Cohorts C, Period 2, Participants will receive a single oral 130 mg dose of evacetrapib on Days 5-14.
Part 2, Cohorts C, Period 3, Participants will receive evacetrapib 130 mg orally and atorvastatin 20 mg orally, once daily on Days 15 - 22.</description>
          </group>
        </group_list>
        <measure>
          <title>PK: Cmax of Evacetrapib Alone and With Simvastatin or Atorvastatin</title>
          <description>Pharmacokinetic parameter estimates of evacetrapib following 130 mg evacetrapib daily alone or with 40 mg simvastatin or 20 mg atorvastatin daily.</description>
          <population>All participants who received at least one dose of study drug in Cohort B and C and had evaluable PK data.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Days 5-14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1180" spread="52"/>
                    <measurement group_id="O2" value="1120" spread="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 15- 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1020" spread="68"/>
                    <measurement group_id="O2" value="1000" spread="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>PK: Tmax of Evacetrapib Alone and With Simvastatin or Atorvastatin</title>
        <description>Pharmacokinetic parameter estimates of Tmax of evacetrapib following 130 mg daily dose alone or with 40 mg Simvastatin or 20 mg Atorvastatin. Tmax of simvastatin and atorvastatin.</description>
        <time_frame>Part 2: Predose on Day 14 and 22 and at 0.5, 1, 2, 3, 4, 6, 8, 12, and 24 hours postdose.</time_frame>
        <population>All participants who received at least one dose of study drug in Cohort B and C and had evaluable PK data.</population>
        <group_list>
          <group group_id="O1">
            <title>Evacetrapib Daily and Simvastatin</title>
            <description>Part 2, Cohorts B, Period 2, Participants will receive a single oral 130 mg dose of evacetrapib on Days 5-14
Part 2, Cohorts B, Period 3, Participants will receive evacetrapib 130 mg and simvastatin 40mg orally, once daily on Days 15 - 22.</description>
          </group>
          <group group_id="O2">
            <title>Evacetrapib Daily and Atrovastatin</title>
            <description>Part 2, Cohort C, Period 2, Participants will receive a single oral 130 mg dose of evacetrapib on Days 5-14
Part 2, Cohort C, Period 3, Participants will receive evacetrapib 130 mg orally and atorvastatin 20 mg orally, once daily on Days 15 - 22.</description>
          </group>
        </group_list>
        <measure>
          <title>PK: Tmax of Evacetrapib Alone and With Simvastatin or Atorvastatin</title>
          <description>Pharmacokinetic parameter estimates of Tmax of evacetrapib following 130 mg daily dose alone or with 40 mg Simvastatin or 20 mg Atorvastatin. Tmax of simvastatin and atorvastatin.</description>
          <population>All participants who received at least one dose of study drug in Cohort B and C and had evaluable PK data.</population>
          <units>h</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Days 5-14</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.00" lower_limit="2.00" upper_limit="4.00"/>
                    <measurement group_id="O2" value="3.00" lower_limit="2.00" upper_limit="6.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Days 15- 22</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.00" lower_limit="2.00" upper_limit="4.00"/>
                    <measurement group_id="O2" value="3.00" lower_limit="2.00" upper_limit="4.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Effect of Evacetrapib Single and Multiple Doses on High Density Lipoprotein Cholesterol (HDL-C), Low Density Lipoprotein Cholesterol (LDL-C), and Triglycerides (TG)</title>
        <time_frame>Single Dose Day 2 and Multiple Dose Day 22</time_frame>
        <population>All participants who received at least one dose of study drug in Cohort A.</population>
        <group_list>
          <group group_id="O1">
            <title>Evacetrapib Single Dose Day 2</title>
            <description>Part 1, Cohort A, Period 1, Participants will receive a single oral 130 mg dose of evacetrapib.</description>
          </group>
          <group group_id="O2">
            <title>Evacetrapib Multiple Dose Day 22</title>
            <description>Part 1, Cohort A, Period 2, Participants will receive multiple doses of evacetrapib 130 mg for 14 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Effect of Evacetrapib Single and Multiple Doses on High Density Lipoprotein Cholesterol (HDL-C), Low Density Lipoprotein Cholesterol (LDL-C), and Triglycerides (TG)</title>
          <population>All participants who received at least one dose of study drug in Cohort A.</population>
          <units>millimoles per liter (mmol/L)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HDL-C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.641" spread="0.211"/>
                    <measurement group_id="O2" value="2.676" spread="0.373"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL-C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.289" spread="0.483"/>
                    <measurement group_id="O2" value="1.241" spread="0.574"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TG</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.984" spread="0.312"/>
                    <measurement group_id="O2" value="1.221" spread="0.356"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Evacetrapib Single Cohort A</title>
          <description>Part 1, Cohort A, Period 1, Participants will receive a single oral 130 mg dose of evacetrapib.</description>
        </group>
        <group group_id="E2">
          <title>Evacetrapib Multiple</title>
          <description>Part 1, Cohort A, Period 2, Participants will receive multiple doses of evacetrapib 130 mg for 14 days.</description>
        </group>
        <group group_id="E3">
          <title>Simvastatin</title>
          <description>Part 2, Cohorts B, Period 1, Participants will receive simvastatin 40 mg orally, once daily on Days 1 – 4.</description>
        </group>
        <group group_id="E4">
          <title>Evacetrapib Single Cohort B</title>
          <description>Part 2, Cohorts B, Period 2, Participants will receive a single oral 130 mg dose of evacetrapib on Days 5-14</description>
        </group>
        <group group_id="E5">
          <title>Evacetrapib and Simvastatin</title>
          <description>Part 2, Cohorts B, Period 3, Participants will receive evacetrapib 130 mg and simvastatin 40mg orally, once daily on Days 15 – 22.</description>
        </group>
        <group group_id="E6">
          <title>Atorvastatin</title>
          <description>Part 2, Cohorts C, Period 1, Participants will receive atorvastatin orally, once daily on Days 1 – 4.</description>
        </group>
        <group group_id="E7">
          <title>Evacetrapib Single Cohort C</title>
          <description>Part 2, Cohorts C, Period 2, Participants will receive a single oral 130 mg dose of evacetrapib on Days 5-14</description>
        </group>
        <group group_id="E8">
          <title>Evacetrapib and Atorvastatin</title>
          <description>Part 2, Cohorts C, Period 3, Participants will receive evacetrapib 130 mg orally and atorvastatin 20 mg orally, once daily on Days 15 – 22.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Chief Medical Officer</name_or_title>
      <organization>Eli Lilly and Company</organization>
      <phone>800-545-5979</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

